It is known that the pathophysiology of CRSwNP is characterized by increased tissue levels of IL-5 and, currently, the therapeutic option represented by Mepolizumab, a monoclonal anti-IL5 antibody, is effective in nasal polyposis and it could be useful in preventing a possible recurrence of the disease and consequent revision surgery [33,55]. This evidence concerns the gene IL5 and chronic rhinosinusitis with nasal polyps.